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Abstract
Background The purpose of this study is to compare effects of
different nations on Roux-en-Y gastric bypass (RYGB) vs.
intensive medical management (IMM) in achieving remission
of type 2 diabetes mellitus (T2DM).
Materials and Methods Between April 2008 and December
2011, this randomized, controlled clinical trial was conducted
at four teaching hospitals in the United States and Taiwan
involving 71 participants with mild obesity (BMI 30–35 kg/
m2). Thirty-six of 71 participants were randomly assigned to
the RYGB group, and the others were in IMM group. Partial
or complete remission of T2DM was defined as blood
HbA1c < 6.5 % (48 mmol/mol) or <6 % (42 mmol/mol) with-
out any antihyperglycemic medication for at least 1-year du-
ration, respectively.
Results At baseline, Taiwanese participants had a lower BMI,
younger age, and shorter duration of T2DM than American
participants. At 24 months, weight loss was greater in the
RYGB group in both populations than in the IMM group.
No IMM participant of either population had partial or com-
plete remission of T2DM. In the RYGB group, a substantial
proportion of the subjects achieved complete or partial
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remission (57 % in Taiwanese and 27 % in American partic-
ipants, P = 0.08). Logistic regression revealed stimulated C-
peptide (Odds ratio 2.22, P = 0.02) but not nationality as a
significant predictor of diabetes remission.
Conclusion Adding RYGB to lifestyle and medical manage-
ment was associated with a greater likelihood of remission of
T2DM in both Taiwanese and American subjects with mild
obesity with type 2 diabetes. Residual beta-cell function at
baseline appears to be the major factor predicting remission
of T2DM.
Trial registry number: clinicaltrials.gov Identifier:
NCT00641251
Keywords Diabetes remission . Type 2 diabetesmellitus .
Roux-en-Y gastric bypass . National differences . Ethnic
differences . Taiwanese
Abbreviations
DSS Diabetes surgery study
IMM Intensive medical management
RYGB Roux-en-Y gastric bypass
CI Confidence interval
T2DM Type 2 diabetes mellitus
Introduction
Type 2 diabetes mellitus (T2DM) is a major chronic debilitat-
ing disease worldwide, affecting more than 387 million peo-
ple, and that number is expected to 592 million by the year
2035 [1]. The development of T2DM is strongly associated
with central obesity or the accumulation of intra-abdominal
fat. T2DM is a particular problem in Asia because of a ten-
dency to develop T2DM at a lower BMI [2]. The prevalence
has recently increased 3–6 fold within 20–25 years in Asia [3].
In Taiwan, T2DM in adults has more than doubled from 4.6 to
9.3 % of the population in the past decade [4]. Unlike in the
West where the older population is the most affected, the bur-
den of diabetes in Asian countries is disproportionately high in
young to middle-age adults [2, 3].
Controlling this chronic and debilitating disease is a very
important health issue in Asia. Medications to improve glyce-
mia and control cardiovascular risk are important, but up to
90 % of patients with T2DM do not achieve treatment goals
designed to decrease the long-term risk of complications [5].
In the 2007–2010 diabetic NHANES population, 52.5 % of
people with diabetes achieved a blood HbA1c < 7.0 %
(<53 mmol/mol), 51.1 % achieved BP < 130/80 mmHg,
56.2 % achieved LDL < 100 mg/dL (2.586 mmol/L), and
18.8 % achieved all three as a composite goal [6]. In a similar
2011 Taiwan national survey after a policy of diabetes aware-
ness, 34.5 % of people with diabetes achieved HbA1c < 7 %
(<53 mmol/mol), 37.7 % achieved a blood pressure target
<130/80 mmHg, 55.7 % achieved total cholesterol <160 mg/
dl (4.14 mmol/L) or LDL cholesterol lower than 100 mg/dl
(2.59 mmol/L), and 8.6 % achieved all three [7].
Bariatric surgery has been advocated to improve the
disordered metabolism present in T2DM. Evidence fa-
voring improvement in the outcomes of T2DM after
bariatric surgery is provided by observational studies
[8, 9] and early reports from randomized trials [10,
11] in both Taiwanese and American cohorts. A meta-
analysis of ethnic differences in weight loss and remis-
sion of T2DM after bariatric surgery had been published
[12], but no comparison between Asian and American
has been reported. The Diabetes Surgery Study is the
first randomized, controlled trial to enroll both
Taiwanese and American participants.
This subgroup analysis aimed to compare the impact of
RYGB with lifestyle modification with IMM alone to achieve
remission of T2DM in Asians compared to a US cohort with
BMI 30–35 kg/m2.
Methods
Study Design and Participants
The DSS study design and participants have been previ-
ously reported [13, 14]. The study was conducted at four
sites: the University of Minnesota, Columbia University
Medical Center in New York, the Mayo Clinic in
Rochester, and two academic clinics in Taiwan
(National Taiwan University Hospital and Min Sheng
General Hospital, together called Taiwan). Institutional
Review Board approval and written informed consent
from each patient was obtained at all sites.
Inclusion and exclusion criteria have been also re-
ported previously [13, 14]. Key inclusion criteria includ-
ed blood levels of HbA1c of 8.0 % (64 mmol/mol) or
greater despite at least 6 months of care by a physician
for T2DM, BMI 30.0–35 kg/m2, and willingness and
ability to accept randomization and follow the full treat-
ment protocol. Exclusion criteria included the conditions
that would contraindicate surgery, such as serious car-
diovascular disease, previous gastrointestinal surgery,
psychologic concerns, or history of malignancy.
Patients were randomized within sites to either inten-
sive medical management (IMM) or lifestyle and medi-
cal management plus a RYGB, using a random, permut-
ed block design. Clinical center personnel had access to
data on their individual patients but were blinded to
data on other patients and to aggregated data until all
two-year follow-up data had been obtained.
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Procedures
The procedures of DSS have been previously reported [13,
14]. The lifestyle intervention was modeled on recent, suc-
cessful clinical trials, particularly the Diabetes Prevention
Program (DPP) [15] and the Look AHEAD protocol [16].
Visits with an endocrinologist occurred monthly for 6 months
and then quarterly (or monthly if not at goal) for the next
6 months, then quarterly through the second year.
Medications for glycemic control were added or reintroduced
in the following order: metformin, a glucagon-like peptide-1
receptor agonist or a dipeptidyl peptidase-4 inhibitor, sulfo-
nylurea or pioglitazone, and insulin.
The technique of RYGB was standardized across all sites
and performed with construction of a 20-mL lesser curvature
gastric pouch a 100-cm biliopancreatic limb. All surgeons
committed to following this protocol which was reviewed at
an onsite meeting. The technical skill of each surgeon was
established by personal observation of the principal surgeon.
The study surgeons performed all postoperative surgical
interventions.
Outcomes
Partial remission of T2DM was defined as HbA1c < 6.5 %
(48 mmol/mol), and complete remission as HbA1c < 6.0 %
(42 mmol/mol), at every sampling from months 12 to 24 with
no medicines for hyperglycemia in the RYGB group. These
definitions are in line with the recommendations of a consen-
sus statement by the American Diabetes Association [17]. We
obtained data at baseline, medical visits, and lifestyle interven-
tion visits. For each group, baseline measurements were taken
at the time of randomization. The data includedmeasurements
of height, weight, blood pressure, waist circumference, med-
ication used, and adverse events. Laboratory measurements
included blood levels of HbA1c, fasting lipid profile, com-
plete blood cell count, electrolytes, hepatic panel, ferritin, vi-
tamin B1, vitamin B12, vitamin D, parathyroid hormone, cal-
cium, fasting blood glucose and C-peptide levels, 90-min
post-meal glucose and C-peptide levels, and urine
microalbumin to creatinine ratios.
Statistical Analysis
Statistical analyses were performed in SAS 9.3 (SAS Institute,
Cary NC). All analyses were done on an intention to treat
basis. Multiple imputations were conducted to address the
issue of missing data using PROC MI in SAS. Forty imputa-
tions were done. Data from baseline, 12 and 24 months were
included in the model. Information on crossover was also
included.
Data are presented as mean (SD) for continuous variables
and N (%) for categorical variables. Dichotomous data were
analyzed using logistic regressions stratified by site.
Continuous data were analyzed using linear regressions ad-
justed for site. Regressions were done separately for each im-
putation and then summarized using PROC MIANALYZE.
Potential predictors of remission were examined individu-
ally using logistic regressions, and those variables with
P < 0.10were included in the multivariate models. Odds ratios
and their 95 % confidence intervals are presented.
Results
Between April 2008 and December 2011, 120 patients were
randomized either to the IMM or RYGB groups of whom 71
patients had mild obesity (BMI 30–35 kg/m2); 35 participants
(19 Americans and 16 Taiwanese) were enrolled in IMM
group, and 36 participants (22 Americans and 14 Taiwanese)
in RYGB group.
Baseline characteristics of two populations with mild obe-
sity are shown in Table 1. BMI (31.9 ± 1.7 vs. 32.9 ± 1.5 kg/
m2, P = 0.016) and waist circumference (102.7 ± 6.4 vs.
112.2 ± 7.4 cm, P < 0.001) in Taiwanese participants were
significantly less than in American participants. Taiwanese
participants also tended to be younger (45.7 ± 7.9 years vs.
50.7 ± 8.9 years, P = 0.014). The duration of T2DM in
Taiwanese was less (6.1 ± 3.6 vs. 10.4 ± 6.5 years,
P = 0.0006), while fewer Taiwanese took insulin (33 % vs.
59 %, P = 0.036). More American participants took blood
pressure medications (76 % vs. 43 %, 0.006), but no signifi-
cant difference in baseline systolic blood pressure were noted.
Fasting serum levels of C-peptide and 90-min postprandial C-
peptide (stimulated C-peptide) did not differ in the two
populations.
Table 2 shows the outcomes of two populations in the IMM
and RYGB group at 24 months. In the IMM group, no signif-
icant difference in achieving treatment targets and major met-
abolic markers were found in these two populations. There
were fewer Taiwanese taking insulin and blood pressure med-
ications. In the RYGB group, patients lost more weight than in
the IMM group, but in the RYGB group, there were no sig-
nificant difference in percent weight change (−21.2 ± 6.1 vs.
−24.52 ± 10.7 %, P = 0.45) was noted between these two
populations. Taiwanese participants had greater reduction in
SBP and DBP but no significant different in achieving the
targets of SBP < 130 mmHg (86 % vs. 90 %, P = 0.84).
Both populations had similar effect on glucose reduction and
achieving HbA1c target (86 % vs. 67 %, P = 0.20).
At 24 months, no participant in either of populations of the
IMM group achieved partial or complete remission. In con-
trast, in the RYGB group, the proportion of complete remis-
sion was 29 % and 14 % in the Taiwanese and American
populations, respectively (P = 0.39). Overall, the proportion
of complete or partial remission in Taiwanese and American
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participants was 57 % and 27 %, respectively (P = 0.08) (as
Table 3).
A univariate analysis showed that lower fasting glu-
cose, higher stimulated C-peptide, and non-insulin use
before RYGB predict complete or partial remission at
24 months in the RYGB patients. A multivariate analy-
sis of predictors with P value <0.10 (except for fasting
C-peptide, because it is highly correlated with stimulat-
ed C-peptide) showed that stimulated C-peptide is a
significant predictor of DM remission (OR 2.22,
P = 0.02) (as Table 4).
Discussion
In this report, we found that baseline BMI and waist circum-
ference in Taiwanese participants were significantly less than
in American participants. Taiwanese participants were slightly
younger than the American cohort. In Asia, T2DM is charac-
terized by onset at a relatively low BMI and a younger age [2].
Fewer Taiwanese participants were taking insulin and blood
pressure medicines than American participants at the baseline
of the DSS study. Nevertheless, uncontrolled T2DM remains a
common problem in Taiwan [7].







Age 45.7 (7.9) 50.7 (8.9) 0.014
Female 22 (73 %) 24 (59 %) 0.20
Race/Ethnicity
Non-Hispanic White 0 31 (76 %)
Asian 30 (100 %) 1 (2 %) –
Non-Hispanic Black 0 4 (10 %)
Hispanic 0 3 (7 %)
Native American 0 0 (0 %)
Other 0 2 (5 %)
BMI (kg/m2) 31.9 (1.7) 32.9 (1.5) 0.016
Height (cm) 161.5 (6.4) 170.4
(10.3)
<.0001
Weight (kg) 83.4 (8.3) 95.8 (12.5) <.0001
Waist circumference (cm) 102.7 (6.4) 112.2 (7.4) <.0001
SBP (mmHg) 128.0 (14.7) 127.7
(13.1)
0.93
DBP (mmHg) 81.8 (9.4) 74.3 (10.1) 0.002
Years since diagnosis of T2DM 6.1 (3.6) 10.4 (6.5) 0.0006
Blood HbA1c (%) 9.56 (1.14) 9.76 (1.25) 0.49
LDL cholesterol (mmol/L) 2.92 (0.92) 2.59 (1.19) 0.19
HDL cholesterol (mmol/L) 1.08 (0.22) 1.10 (0.30) 0.68
Triglycerides (mmol/L) 2.46 (2.08) 3.24(5.34) 0.40
Total cholesterol (mmol/L) 4.75 (0.98) 4.85 (1.35) 0.70
Creatinine (μmol/L) 65.1 (14.4) 69.00
(18.64)
0.33
Fasting C-peptide (nmol/L) 1.05 (0.66) 0.90 (0.45) 0.28
Stimulated C-peptide (nmol/L) 1.70 (1.00) 1.35 (0.61) 0.093
Fasting glucose (mmol/L) 10.88 (3.04) 13.22
(4.49)
0.011
Taking insulin 10 (33 %) 24 (59 %) 0.036
Taking other glycemic medicines 28 (93 %) 37 (90 %) 1
Taking dyslipidemia medicines 16 (53 %) 29 (71 %) 0.13
Taking blood pressure medicines 13 (43 %) 31 (76 %) 0.006
Number of medications for control of glycemia, dyslipidemia, and
blood pressure
3.4 (1.3) 4.2 (1.4) 0.015
US United States, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c
glycated hemoglobin, LDL cholesterol low density lipoprotein cholesterol, HDL cholesterol high density lipo-
protein cholesterol
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In the first year of the DSS study, 47 % of the observed
participants randomized to Roux-en-Y gastric bypass (RYGB)
reached the triple endpoint goal compared with only 19 % of
the participants randomized to treatment with (IMM) [13].
The proportion of participants achieving the triple endpoint
goal decreased to 43 % and 14 % ,respectively, at 2 years with
only 25 % of the gastric bypass group maintaining a complete
remission of T2DM, and 42 % achieving partial remission
[14].
In the 2-year report of the DSS, 36 % Taiwanese partici-
pants and 52 % American participants in the RYGB group
achieved the triple endpoints, while only 19 % Taiwanese
participants and 7 % American participants in IMM group
achieved the triple endpoints; 86 % Taiwanese participants
and 67 % American participants in RYGB group achieved
the HbA1c target (<7.0 %) (53 mmol/mol), while only 19 %
Taiwanese participants and 20 % American participants in
IMM group achieved the target. No participant in either pop-
ulation in the IMM group met the definition of partial or com-
plete remission of T2DM. Only 27 % of American and 57 %
Taiwanese participants of the RYGB group achieved complete
or partial remission of T2DM, less than reported in other trials.
Lee and colleagues reported a randomized control trial to
compare RYGB vs. sleeve gastrectomy for T2DM [11].
Remission of T2DM, defined as HbA1c <6.5 % (48 mmol/
mol), was achieved by 28 (93 %) in the RYGB group and 14
(47%) in the sleeve gastrectomy group. The STAMPEDE trial
found 46 % of the RYGB group to have a HbA1c < 6.5 %
Table 2 Key outcomes at 24 months













Meets triple endpoint 3 (19 %) 1 (7 %) 0.25 5 (36 %) 11 (52 %) 0.40
HbA1c < 7.0 % (53 mmol/mol) 3 (19 %) 3 (20 %) 0.99 12 (86 %) 14 (67 %) 0.20
LDL cholesterol <100 mg/dL 13 (81 %) 10 (67 %) 0.17 8 (57 %) 17 (81 %) 0.20
SBP < 130 mmHg 13 (81 %) 10 (67 %) 0.21 12 (86 %) 19 (90 %) 0.84
Change in weight (kg) −4.2 (4.5) −8.1 (7.9) 0.36 −18.4 (5.9) −24.2
(11.2)
0.13
Percent weight change −5.1 (5.5) −8.8 (8.2) 0.48 −21.2 (6.1) −24.5
(10.7)
0.45
Change in BMI −1.9 (1.9) −2.8 (2.5) 0.47 −6.9 (2.1) −8.1 (3.6) 0.34
Change in waist circumference (cm) −4.8 (5.1) −8.2 (9.1) 0.21 −20.8 (9.7) −22.2 (9.7) 0.68
Change in fasting glucose (mmol/L) −1.04 (3.49) −2.35
(4.42)
0.11 −5.30 (2.64) −6.50
(5.22)
0.32
Change in HbA1c (%) −0.59 (1.52) −1.41
(1.56)
0.19 −3.24 (1.05) −2.83
(1.58)
0.49
Change in LDL-C (mmol/L) −0.38 (1.19) −0.39
(1.27)
0.87 −0.87 (1.16) −0.30
(0.82)
0.09
Change in HDL-C (mmol/L) −0.02 (0.22) 0.02 (0.23) 0.75 0.24 (0.21) 0.24 (0.45) 0.97
Change in triglycerides (mmol/L) 0.21 (3.20) −0.13
(2.17)
0.98 −0.92 (0.65) −2.30
(6.92)
0.48





Change in creatinine (μmol/L) 0 (9.7) 6.1 (20.5) 0.30 −7.58 (7.55) −0.55
(20.0)
0.22
Change in fasting C-peptide (nmol/L) −0.13 (0.36) −0.11
(0.42)
0.57 −0.44 (0.98) −0.22
(0.34)
0.38
Change in post-meal C-peptide (nmol/L) −0.08 (0.72) 0.01 (0.65) 0.67 −0.27 (1.31) 0.11 (0.70) 0.35
Change in SBP −9.1 (12.4) −2.8 (18.6) 0.19 −16.1 (14.1) −5.8 (14.4) 0.03
Change in DBP −4.1 (7.9) -0.5 (10.1) 0.54 −13.2 (6.7) −5.8 (10.1) 0.02
Taking Insulin 3 (19 %) 9 (60 %) 0.03 0 (0 %) 4 (19 %) 0.13
Taking other glycemic medicines 15 (94 %) 14 (93 %) 0.42 4 (29 %) 11 (52 %) 0.18
Taking dyslipidemia medicines 14 (88 %) 9 (60 %) 0.11 7 (50 %) 10 (48 %) 0.95
Taking blood pressure medicines 5 (31 %) 11 (73 %) 0.04 3 (21 %) 8 (38 %) 0.26
Number of medications for control of glycemia, dyslipidemia, and blood
pressure
3.9 (1.6) 4.6 (2.0) 0.54 1.1 (1.0) 1.9 (1.6) 0.08
USUnited States, BMI body mass index, SBP systolic blood pressure,DBP diastolic blood pressure,HbA1c glycated hemoglobin, LDL cholesterol low
density lipoprotein cholesterol, HDL cholesterol high density lipoprotein cholesterol
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(48 mmol/mol) without medication at 3 years [18]. The
Longitudinal Assessment of Bariatric Surgery (LABS) con-
sortium, a multicenter observational cohort study at 10 US
hospitals in six geographically diverse clinical centers, report-
ed 67.5 % of participants with T2DM achieving partial remis-
sion [8]. A multi-institutional, international study enrolling
five Asian countries reported 79.3 % of patients undergoing
RYGB achieved remission of T2DM, it defined as
HbA1c < 6.0 % (42 mmol/mol) [9]. Possible explanations
for the lower rate of remission in our study include greater
severity of disease with a mean HbA1c of 9.6 % (81 mmol/
mol) and a greater duration of T2DM—8.9 years in our pop-
ulation, although other randomized trials with higher rates of
remission have included participants with average durations
of T2DM of 6.4 to 10.4 years. It is also possible that our
definition of remission was more rigorous by requiring a
sustained HbA1c below the target value without diabetes
medication at all visits from 12 to 24 months.
In our current report, 27 % of American and 57 %
Taiwanese participants in the RYGB group achieved complete
or partial remission of T2DM 2 years post-surgery (P = 0.08).
The difference is not statistically significance in univariate and
multivariate analysis, which may be limited by small sample
size. The pathophysiology of T2DM is quite different in Asian
vs. Caucasian populations. β-cell dysfunction with delayed
and decreased insulin secretion appears to play a key role in
the progression of T2DM especially in Asian populations
[19]. Lee and colleagues [20] reported that RYGB facilitates
immediate improvement in the glucose metabolism of inade-
quately controlled, mildly obese patients with T2DM, and the
benefit is sustained up to 2 years after RYGB. The benefit in
control of T2DM after RYGB appears to be mediated by a
decrease in insulin resistance, an increase in early insulin re-
sponse, and the total insulin secretion to glucose load [20].
National or ethnic differences in the response of T2DM to
RYGB appear to exist and need further evaluation.
Lee and colleagues reported that remission rates of T2DM
after RYGB were positively correlated with preoperative C-
peptide levels, suggesting that this biomarker may be used to
assist in the selection of patients with obesity-related T2DM
for bariatric surgery [21]. In this 2-year report of DSS, we
confirm that stimulated C-peptide is also a predictor of diabe-
tes remission. Major limitation of this study is relatively small
sample size to compare these two populations.
Conclusion
This is the first randomized, controlled trial enrolling both
Taiwanese and Americans comparing RYGB to a lifestyle
intervention control group. In patients with mild obesity and
T2DM, adding RYGB to lifestyle and medical management
was associated with a greater likelihood of remission of dia-
betes in both Taiwanese and American. The residual beta-cell
function of the participants appears to be the major factor to
predict the remission. National or ethnic differences in re-
sponse of T2DM to RYGB are still not clear. Larger and lon-
ger trials will be needed to fully evaluate the role of bariatric
surgery in different populations, including effects and side
Table 4 Predictors of complete or partial remission at 24 months in
RYGB patients
OR (95 % CI) P value
Univariate analysis*
Nationality (Taiwan vs. US) 3.56 (0.86, 14.63) 0.08
Fasting glucose 0.984 (0.970, 0.999) 0.037
Fasting C-peptide 1.86 (0.92, 3.75) 0.084
Stimulated C-peptide 2.47 (1.23, 4.94) 0.011
On insulin 0.21 (0.05, 0.88) 0.033
Multivariate analysis#
Model 1 AIC = 41.170
Nationality (Taiwan vs. US) 2.04 (0.32,13.09) 0.45
Fasting glucose 0.99 (0.97, 1.005) 0.16
Stimulated C-peptide 2.17 (1.02, 4.58) 0.04
On insulin 0.84 (0.12,6.04) 0.86
Model 2: AIC = 39.202
Taiwan 2.16 (0.38,12.38) 0.39
Fasting glucose 0.99 (0.97, 1.004) 0.16
Stimulated C-peptide 2.22 (1.11, 4.47) 0.025
Model 3: AIC = 37.954
Fasting glucose 0.99 (0.97, 1.004) 0.15
Stimulated C-peptide 2.22 (1.13, 4.34) 0.02
Model 4: AIC = 39.148
Stimulated C-peptide 2.47 (1.23, 4.94) 0.011
OR odd ratio, US United States, RYGB Roux-en-Y gastric bypass, AIC
Akaike information criterion
*The following variables has P values of >0.10: age, sex, years since
diagnosis of T2DM, BMI, waist, weight change from baseline to
24 months, HbA1c, SBP, DBP, LDL-C, HDL-C, triglycerides, total cho-
lesterol, on non-insulin antidiabetic meds, on statins, on non-statin lipid-
lowering meds, on BP meds, number of meds for control of glycemia,
dyslipidemia, and BP
# Predictors in univariate analysis with P value <0.10 (except for fasting
C-peptide since it is highly correlated with stimulated C-peptide) were
included. Smaller AIC values are better.







US (N = 22) 3 (14 %) 3 (14 %) 6 (27 %)
Taiwan
(N = 14)
4 (29 %) 4 (29 %) 8 (57 %)
P value 0.39 0.39 0.08
US United States, RYGB Roux-en-Y gastric bypass
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effects. While the long-term risks and benefits of bariatric
surgery should be weighed, the generalizing short-term to
medium-term effects of RYGB for T2DM onWestern cohorts
and Asian populations appears appropriate.
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